Needham analyst Michael Matson has maintained their bullish stance on LIVN stock, giving a Buy rating on October 31. Michael Matson has given ...

This could lead to FDA approvals for treatment in obstructive sleep apnea, kidney disease, Alzheimer’s disease, liver disease ...

Think of the heart as a pump that works tirelessly every day. But sometimes, this pump starts to weaken, which is what ...

While the solutions for an unhealthy diet and lack of exercise are clear, the solutions for sleep apnea are less clear. There ...

LivaNova (Nasdaq:LIVN) today announced that its OSPREY trial of nerve stimulation for treating sleep apnea met its primary ...

It's been more than a year since Apple Watch Ultra 2 launched, and we've had the wearable that's only gotten better on our ...

The Galaxy Watch is the most mainstream of Samsung's ranges and is designed to compete directly with the Apple Watch. The ...

Do you suffer from sleep apnea and long for a peaceful night’s sleep and solution to your snoring? Holy Cross Medical Group pulmonologist Ronald Scott, M.D. will speak about Inspire®, an FDA-approved ...

Inspire Medical Systems shares are up today on third-quarter results that came in ahead of the consensus forecast.

Inspire Medical Systems topped Q3 expectations, signaling continued market strength and innovation.

Inspire is increasing its full year 2024 revenue guidance to between $793 million to $798 million, which represents growth of 27% to 28% over full year 2023 revenue of $624.8 million. This compares to ...